SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, and Doug Atkinson, Head of Global Sales, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October 9, 2025, in New York, NY. If you are interested in arranging a one-on-one meeting wi ...

Core Viewpoint - CapsoVision, Inc. has successfully completed its initial public offering (IPO) of 5,500,000 shares at a price of $5.00 per share, raising gross proceeds of $27.5 million before expenses [1][2]. Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [4]. - The company is developing a pipeline product, CapsoCam Colon, aimed at non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [4]. IPO Details - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CV" on July 2, 2025 [1]. - The underwriters have a 30-day option to purchase an additional 825,000 shares at the IPO price [1]. - The offering was managed by The Benchmark Company, LLC and Roth Capital Partners [2]. Regulatory Information - A registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025, allowing the offering to proceed [3].

Core Points - CapsoVision, Inc. has announced the pricing of its initial public offering (IPO) of 5,500,000 shares at $5.00 per share, with trading expected to begin on July 2, 2025 [1] - The offering is projected to generate gross proceeds of approximately $27.5 million before deducting underwriting discounts and commissions [2] - The company has granted underwriters a 30-day option to purchase an additional 825,000 shares at the IPO price [2] Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4] - The flagship product, CapsoCam Plus®, is a wire-free capsule endoscope that provides high-resolution visualization of the small bowel [4] - The upcoming product, CapsoCam Colon, aims to facilitate non-invasive colon imaging and polyp detection, with plans to expand across various gastrointestinal indications [4]